Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that the design of the ongoing phase I/II study of birinapant in combination with Keytruda® (pembrolizumab) in advanced cancer patients will be presented during the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting, which will take place from 1-5 June 2018 in Chicago, USA.
The poster presentation will be given by the study’s lead investigator, Prof. Russell J. Schilder, Director of the Medical Gynecologic Oncology Program at Thomas Jefferson University Hospital in Philadelphia, USA, as indicated below:
Monday June 4, 08:00 AM – 11:30 AM (local time):
Abstract TPS3131: A phase 1/2 study with birinapant in combination with pembrolizumab
Authors: Russell J. Schilder, Mark Albertella, James Strauss, Malin Sydvander, Santosh M. Nair, Kingsley Urakpo, Stefan Norin, John Öhd
View the full abstract here: https://meetinglibrary.asco.org/record/165273/abstract.
As a Trial in Progress (TPS) presentation, no results from the trial will be presented. The purpose of a trial in progress presentation, as outlined in the ASCO Annual meeting guidelines, is to “provide an opportunity for members of the research community to present ongoing trials, foster collaboration, and discuss correlatives and novel trial designs. In addition, Trials in Progress highlight the transition of emerging biologic pathways and new agents into the clinic—providing "coming attractions" for oncologists in clinical practice”.
Details of all presentations for the 2018 ASCO annual meeting are available at the conference website: https://am.asco.org/program
For further information, please contact:
Erik Björk, CFO, Medivir AB, mobile: +46 (0)72 228 2831
John Öhd CMO, Medivir AB, mobile: +46 (0)72 529 62 00
Birinapant is being developed to enhance responses, and extend survival, of patients with solid tumors where existing treatments do not provide sufficient survival benefit, or where patients no longer have treatment options. Based on its unique design and mechanism, birinapant has the potential to enhance patients’ responses in combination with other treatments. Medivir’s initial focus is on developing birinapant in combination with Keytruda®.
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.